SNDX — Syndax Pharmaceuticals, Inc.
$13.40-1.25%
Last close: · regular session
Last 60 sessions
SNDX closed at $13.40 (-1.25%) on Oct 23, 2026. Float: 73.3M shares. Latest SEC filing: SCHEDULE 13G on Aug 7, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for SNDX in the TickerWise workspace.
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 270
- Website: https://www.syndax.com
Latest SEC filings for SNDX
Latest SNDX news
- Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026 Read article
- Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal Read article
- Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX) Read article
- Syndax Pharmaceuticals Suffers Pipeline Blow Read article
- Syndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session Read article
- Syndax plummets as IPF asset axatilimab fails in phase 2 trial Read article
- Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis Read article
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.